EC approves Erbitux combination for first‑line treatment of BRAF V600E‑mutant mCRC
Breakwater data show significant survival gains over standard chemotherapy Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its indication to include first‑line use in combination with …